Your session is about to expire
What is Adriamycin Pfs
DoxorubicinThe Generic name of this drug
Treatment SummaryDoxorubicin is an antibiotic used to treat cancer. It comes from a type of bacteria called Streptomyces peucetius var. caesius. The drug works by binding to the DNA of cancer cells and preventing them from growing and spreading.
Doxorubicin Hydrochlorideis the brand name
Adriamycin Pfs Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Doxorubicin Hydrochloride
Doxorubicin
1987
117
Approved as Treatment by the FDA
Doxorubicin, otherwise known as Doxorubicin Hydrochloride, is approved by the FDA for 1 uses which include Multiple Myeloma .Multiple Myeloma
Used to treat Multiple Myeloma (MM) in combination with Bortezomib
Effectiveness
How Adriamycin Pfs Affects PatientsDoxorubicin is a medication used to treat different types of cancer. It works by interfering with the DNA of cancer cells and stopping them from growing. It is often used to treat solid tumors, while other forms of the drug are used to treat leukemia. Doxorubicin can also stop the activity of certain enzymes, affect gene expression, and cause damage to DNA. This drug is not specific to any stage of the cell cycle, so it affects all cancer cells.
How Adriamycin Pfs works in the bodyDoxorubicin works by blocking the activity of an enzyme called topoisomerase II. It also forms a complex with DNA, preventing cells from reproducing. These two mechanisms work together to stop the spread of cancer cells.
When to interrupt dosage
The prescribed measure of Adriamycin Pfs is dependent upon the diagnosed condition, such as Malignant Lymphomas, Neoplasms and Sezary Syndrome. The dosage is contingent upon the mode of administration (e.g. Injectable, liposomal or Injection, solution) featured in the table below.Condition
Dosage
Administration
Bladder transitional cell carcinoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Hodgkin's Lymphoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Carcinoma, Bronchogenic
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Malignant Lymphomas
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Neoplasm Metastasis
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Waldenstrom Macroglobulinemia
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Acute Lymphoblastic Leukemia
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Sarcoma, Bone
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
advanced uterine sarcoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
advanced Thymoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Neoplasms
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Thyroid Carcinoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Multiple Myeloma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Neuroblastoma (NB)
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
advanced Soft Tissue Sarcoma (STS)
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Kaposi's Sarcoma AIDS Related
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Mycosis Fungoides (MF)
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Soft Tissue Sarcoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Sezary Syndrome
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Gastric Carcinoma
, 2.0 mg/mL, 5.0 mg/mL, 10.0 mg/mL, 150.0 mg, 50.0 mg, 10.0 mg, 20.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, Injection - Intravenous, Intravenous; Intravesical, Solution, Solution - Intravenous; Intravesical, Solution - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Injection, suspension, liposomal, Injection, suspension, liposomal - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Suspension, Suspension - Intravenous, Injectable, liposomal, Injectable, liposomal - Intravenous, Powder, for solution - Intravenous; Intravesical, Intra-arterial; Intravenous; Intravesical, Injection, powder, lyophilized, for solution - Intra-arterial; Intravenous; Intravesical
Warnings
Adriamycin Pfs has four contraindications and should not be taken while experiencing any of the ailments listed in the subsequent table.Adriamycin Pfs ContraindicationsCondition
Risk Level
Notes
Severe Hepatic Impairment
Do Not Combine
severe persistent drug-induced myelosuppression
Do Not Combine
severe myocardial insuffiency
Do Not Combine
Myocardial Infarction
Do Not Combine
Common Adriamycin Pfs Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Doxorubicin is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Doxorubicin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Doxorubicin.
Abetimus
Major
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Acteoside.
Adriamycin Pfs Toxicity & Overdose RiskThe toxic dose of this drug in rats has been found to be 21800 micrograms per kilogram when administered subcutaneously.
Adriamycin Pfs Novel Uses: Which Conditions Have a Clinical Trial Featuring Adriamycin Pfs?
287 active trials are currently being conducted to explore the efficacy of Adriamycin Pfs in the management of advanced Soft Tissue Sarcoma (STS), Mycosis Fungoides (MF) and advanced Uterine Sarcoma.Condition
Clinical Trials
Trial Phases
Carcinoma, Bronchogenic
3 Actively Recruiting
Phase 3, Phase 1, Phase 2
Advanced Endometrial Cancer
1 Actively Recruiting
Phase 2
Sezary Syndrome
18 Actively Recruiting
Phase 2, Phase 1
Mycosis Fungoides (MF)
0 Actively Recruiting
Neuroblastoma (NB)
1 Actively Recruiting
Early Phase 1
advanced uterine sarcoma
0 Actively Recruiting
Neoplasms
0 Actively Recruiting
Kaposi's Sarcoma AIDS Related
0 Actively Recruiting
Neoplasm Metastasis
1 Actively Recruiting
Phase 2
Multiple Myeloma
12 Actively Recruiting
Phase 2, Phase 1
Gastric Carcinoma
5 Actively Recruiting
Phase 2, Early Phase 1, Not Applicable
Hodgkin's Lymphoma
73 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable
Thyroid Carcinoma
6 Actively Recruiting
Not Applicable, Phase 2, Phase 1
leukemia
0 Actively Recruiting
advanced Thymoma
0 Actively Recruiting
Waldenstrom Macroglobulinemia
8 Actively Recruiting
Phase 2, Phase 1
advanced Soft Tissue Sarcoma (STS)
8 Actively Recruiting
Phase 1, Phase 2, Phase 3
Soft Tissue Sarcoma
65 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1
Malignant Lymphomas
3 Actively Recruiting
Phase 1
Bladder transitional cell carcinoma
18 Actively Recruiting
Phase 1, Early Phase 1, Phase 2, Phase 3
Adriamycin Pfs Reviews: What are patients saying about Adriamycin Pfs?
4.3Patient Review
11/18/2011 I found this treatment to be effective and easy to use. All in all, I'm quite satisfied with my experience.
1.7Patient Review
1/1/2014 I really dislike this medication. After just two treatments, my neutrophil counts were low, and after the third treatment (with a two week break in between to recover), they were even lower. I also had low hemoglobin counts, which forced me to receive a blood transfusion. I feel nauseated and have more pain in my spine since being on this medication, and I don't know if it's helping or not.
Patient Q&A Section about adriamycin pfs
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are the side effects of Adriamycin?
"nausea and vomiting, diarrhea, loss of appetite, missed menstrual periods, darkening of your skin or nails, weakness, tiredness, and eye redness."
Answered by AI
What is Adriamycin used to treat?
"Adriamycin is a medication used to treat various types of cancers, including breast cancer, bladder cancer, ovarian cancer, and thyroid cancer. It is also used to treat Hodgkin lymphoma, non-Hodgkin lymphoma, and certain types of leukemia."
Answered by AI
What does Adriamycin do to cancer?
"Adriamycin is a cancer medicine that belongs to a class of drugs called anthracyclines. It works by damaging the DNA inside cancer cells, which prevents them from replicating. Adriamycin works at any point in the cell cycle."
Answered by AI
What kind of chemo is Adriamycin?
"Some health care professionals may use the trade names Adriamycin or Rubex instead of the generic drug name Doxorubicin when referring to it. Doxorubicin is an anti-cancer chemotherapy drug, also known as an antineoplastic or cytotoxic drug."
Answered by AI